4//SEC Filing
HA NGOC TUAN 4
Accession 0001225208-12-016974
CIK 0000901219other
Filed
Jul 31, 8:00 PM ET
Accepted
Aug 1, 1:57 PM ET
Size
20.9 KB
Accession
0001225208-12-016974
Insider Transaction Report
Form 4
HA NGOC TUAN
Director
Transactions
- Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−16,000$228,000→ 0 totalExercise: $10.70Exp: 2017-05-03→ Common Stock (16,000 underlying) - Disposition to Issuer
Common Stock
2012-07-30$14.25/sh−4,166$59,366→ 16,807 total - Disposition from Tender
Common Stock
2012-07-30$14.25/sh−16,807$239,500→ 0 total - Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−16,000$228,000→ 0 totalExercise: $2.09Exp: 2019-05-07→ Common Stock (16,000 underlying) - Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−16,000$228,000→ 0 totalExercise: $5.97Exp: 2018-05-08→ Common Stock (16,000 underlying) - Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−25,000$356,250→ 0 totalExercise: $9.38Exp: 2015-12-01→ Common Stock (25,000 underlying) - Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−16,000$228,000→ 0 totalExercise: $11.33Exp: 2016-04-27→ Common Stock (16,000 underlying) - Disposition to Issuer
Non-Employee Director Stock Option - Right to Buy
2012-07-30$14.25/sh−16,000$228,000→ 0 totalExercise: $14.23Exp: 2022-05-17→ Common Stock (16,000 underlying)
Footnotes (7)
- [F1]Each restricted stock unit represents a contingent right to receive one (1) share of Human Genome Sciences, Inc. common stock. These restricted stock units were cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $59,365.50, ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These restricted stock units vested automatically upon consummation of the tender offer on July 30, 2012.
- [F2]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $46,720.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F3]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $56,800.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F4]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $194,560.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F5]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $132,480.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F6]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $320.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
- [F7]This option was cancelled in the tender offer that expired on July 27, 2012 in exchange for a cash payment of $121,750.00, representing the difference between the exercise price of the option and the offer price ($14.25 per share) pursuant to the Merger Agreement between the issuer and GlaxoSmithKline plc. These options vested automatically upon consummation of the tender offer on July 30, 2012.
Documents
Issuer
HUMAN GENOME SCIENCES INC
CIK 0000901219
Entity typeother
Related Parties
1- filerCIK 0001241221
Filing Metadata
- Form type
- 4
- Filed
- Jul 31, 8:00 PM ET
- Accepted
- Aug 1, 1:57 PM ET
- Size
- 20.9 KB